JP2011500600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500600A5 JP2011500600A5 JP2010529094A JP2010529094A JP2011500600A5 JP 2011500600 A5 JP2011500600 A5 JP 2011500600A5 JP 2010529094 A JP2010529094 A JP 2010529094A JP 2010529094 A JP2010529094 A JP 2010529094A JP 2011500600 A5 JP2011500600 A5 JP 2011500600A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- benzamide
- cor
- sulfonyl
- aliphatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 136
- 125000001931 aliphatic group Chemical group 0.000 claims description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 239000001257 hydrogen Substances 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 44
- 229910052757 nitrogen Inorganic materials 0.000 claims description 42
- 229910052717 sulfur Inorganic materials 0.000 claims description 40
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 37
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 28
- -1 2-cyanophenyl Chemical group 0.000 claims description 24
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
- 125000005842 heteroatom Chemical group 0.000 claims description 24
- 239000001301 oxygen Substances 0.000 claims description 24
- 239000011593 sulfur Substances 0.000 claims description 24
- 125000002950 monocyclic group Chemical group 0.000 claims description 20
- 125000004043 oxo group Chemical group O=* 0.000 claims description 20
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 10
- 208000004296 neuralgia Diseases 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 125000006413 ring segment Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 208000004550 Postoperative Pain Diseases 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- 125000002723 alicyclic group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000006561 Cluster Headache Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010021639 Incontinence Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000004404 Intractable Pain Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 206010061533 Myotonia Diseases 0.000 claims description 3
- 206010028836 Neck pain Diseases 0.000 claims description 3
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 3
- 206010033557 Palpitations Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 208000008765 Sciatica Diseases 0.000 claims description 3
- 108010052164 Sodium Channels Proteins 0.000 claims description 3
- 102000018674 Sodium Channels Human genes 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 230000005176 gastrointestinal motility Effects 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
- 208000009935 visceral pain Diseases 0.000 claims description 3
- AVQKFIYCHKRMRS-UHFFFAOYSA-N 2-(4-methoxyphenoxy)-5-nitro-n-(3-sulfamoylphenyl)benzamide Chemical compound C1=CC(OC)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1C(=O)NC1=CC=CC(S(N)(=O)=O)=C1 AVQKFIYCHKRMRS-UHFFFAOYSA-N 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- ZSTQBEVUJOQXMA-UHFFFAOYSA-N n-[5-(diethylsulfamoyl)-2-methoxyphenyl]-2-phenoxybenzamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(OC)C(NC(=O)C=2C(=CC=CC=2)OC=2C=CC=CC=2)=C1 ZSTQBEVUJOQXMA-UHFFFAOYSA-N 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000002981 neuropathic effect Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000000034 method Methods 0.000 description 3
- 0 CC*c(cc1)cc(*c2ccccc2)c1C(*(C)(C)c1cccc(N=O)c1)=O Chemical compound CC*c(cc1)cc(*c2ccccc2)c1C(*(C)(C)c1cccc(N=O)c1)=O 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97928907P | 2007-10-11 | 2007-10-11 | |
| US60/979,289 | 2007-10-11 | ||
| PCT/US2008/079546 WO2009049183A1 (en) | 2007-10-11 | 2008-10-10 | Aryl amides useful as inhibitors of voltage-gated sodium channels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500600A JP2011500600A (ja) | 2011-01-06 |
| JP2011500600A5 true JP2011500600A5 (enExample) | 2012-11-15 |
| JP5562859B2 JP5562859B2 (ja) | 2014-07-30 |
Family
ID=40373086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529094A Active JP5562859B2 (ja) | 2007-10-11 | 2008-10-10 | 電位開口型ナトリウムチャネルの阻害剤として有用なアリールアミド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8779197B2 (enExample) |
| EP (1) | EP2212290B1 (enExample) |
| JP (1) | JP5562859B2 (enExample) |
| KR (1) | KR20100075631A (enExample) |
| CN (1) | CN101883758A (enExample) |
| AU (1) | AU2008310663A1 (enExample) |
| CA (1) | CA2702101A1 (enExample) |
| IL (1) | IL204978A0 (enExample) |
| MX (1) | MX2010003865A (enExample) |
| NZ (1) | NZ584519A (enExample) |
| RU (1) | RU2010118467A (enExample) |
| WO (1) | WO2009049183A1 (enExample) |
| ZA (1) | ZA201002604B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9139529B2 (en) * | 2013-01-31 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Substituted quinoxalines as sodium channel modulators |
| IL269964B1 (en) * | 2013-01-31 | 2025-09-01 | Vertex Pharma | Pyridone amide compounds, compositions containing them and uses thereof |
| BR112015018284B1 (pt) * | 2013-01-31 | 2023-03-07 | Vertex Pharmaceuticals Incorporated | Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica |
| SG11201600383SA (en) * | 2013-07-19 | 2016-02-26 | Vertex Pharma | Sulfonamides as modulators of sodium channels |
| GEP20207082B (en) | 2013-12-13 | 2020-04-10 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| MX386261B (es) * | 2015-10-07 | 2025-03-18 | Univ Arizona | Inhibidores de sumoilacion de crmp2 y usos de los mismos |
| CN110740993B (zh) | 2017-05-16 | 2023-09-01 | 沃泰克斯药物股份有限公司 | 用作钠通道调节剂的氘代吡啶酮酰胺及其前药 |
| AU2018300150A1 (en) * | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CA3091012A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| WO2020014246A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
| EP3820860B1 (en) | 2018-07-09 | 2025-10-15 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting nav1.8 |
| EP3873893A1 (en) | 2018-11-02 | 2021-09-08 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| EP3873468A4 (en) | 2018-11-02 | 2022-10-26 | Merck Sharp & Dohme LLC | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS |
| WO2020140959A1 (zh) * | 2019-01-04 | 2020-07-09 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用 |
| WO2020146682A1 (en) * | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) * | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020169042A1 (zh) * | 2019-02-20 | 2020-08-27 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| CN112390745B (zh) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
| JP2022548104A (ja) * | 2019-09-12 | 2022-11-16 | オリオン コーポレーション | ピリジン窒素酸化物及びその製造方法と使用 |
| HRP20241695T1 (hr) | 2019-12-06 | 2025-02-14 | Vertex Pharmaceuticals Incorporated | Supstituirani tetrahidrofurani kao modulatori natrijevih kanala |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| TWI806073B (zh) | 2020-06-17 | 2023-06-21 | 美商默沙東有限責任公司 | 作為nav1.8抑制劑之2-氧基咪唑啶-4-甲醯胺 |
| CN114031518B (zh) * | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
| KR20240005878A (ko) | 2021-05-07 | 2024-01-12 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 시클로알킬 3-옥소피페라진 카르복스아미드 및 시클로헤테로알킬 3-옥소피페라진 카르복스아미드 |
| KR20240031300A (ko) | 2021-06-04 | 2024-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널 조절제로서의 n-(하이드록시알킬 (헤테로)아릴) 테트라하이드로푸란 카르복스아미드 |
| US11999699B2 (en) | 2021-06-15 | 2024-06-04 | Grünenthal GmbH | Substituted pyrazole amides |
| EP4583867A2 (en) * | 2022-09-09 | 2025-07-16 | Latigo Biotherapeutics, Inc. | Sodium channel blocking compounds, derivatives thereof, and methods of their use |
| EP4385984A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Pyridine-n-oxides as inhibitors of nav1.8 |
| EP4385979A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Multicyclic inhibitors of nav1.8 |
| AR131345A1 (es) | 2022-12-14 | 2025-03-12 | Gruenenthal Gmbh | SULFOXIMINAS COMO INHIBIDORES DE NaV1.8 |
| EP4385980A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Indazoles as inhibitors of nav1.8 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE568115A (enExample) * | 1957-05-29 | 1900-01-01 | ||
| CA1135705A (en) * | 1978-07-20 | 1982-11-16 | Jens-Uwe Bliesener | N-arylsulfonylpyrroles, their preparation, and therapeutic agents containing these compounds |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6620849B2 (en) * | 2000-07-26 | 2003-09-16 | Icafen, Inc. | Potassium channel inhibitors |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| WO2003037274A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| WO2004106324A1 (en) | 2003-05-27 | 2004-12-09 | E.I. Dupont De Nemours And Company | Azolecarboxamide herbicides |
| NZ579370A (en) * | 2003-08-08 | 2011-06-30 | Vertex Pharma | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| CA2586870A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| AU2006260299B8 (en) * | 2005-06-21 | 2012-11-29 | Mitsui Chemicals, Inc. | Amide derivative and insecticide containing the same |
| PE20070589A1 (es) | 2005-10-04 | 2007-06-22 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| US8841483B2 (en) * | 2006-04-11 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
-
2008
- 2008-10-10 AU AU2008310663A patent/AU2008310663A1/en not_active Abandoned
- 2008-10-10 MX MX2010003865A patent/MX2010003865A/es active IP Right Grant
- 2008-10-10 EP EP08838261.9A patent/EP2212290B1/en active Active
- 2008-10-10 JP JP2010529094A patent/JP5562859B2/ja active Active
- 2008-10-10 US US12/249,270 patent/US8779197B2/en active Active
- 2008-10-10 RU RU2010118467/04A patent/RU2010118467A/ru not_active Application Discontinuation
- 2008-10-10 WO PCT/US2008/079546 patent/WO2009049183A1/en not_active Ceased
- 2008-10-10 KR KR1020107010357A patent/KR20100075631A/ko not_active Withdrawn
- 2008-10-10 CN CN2008801184861A patent/CN101883758A/zh active Pending
- 2008-10-10 CA CA2702101A patent/CA2702101A1/en not_active Abandoned
- 2008-10-10 NZ NZ584519A patent/NZ584519A/en not_active IP Right Cessation
-
2010
- 2010-04-08 IL IL204978A patent/IL204978A0/en unknown
- 2010-04-14 ZA ZA2010/02604A patent/ZA201002604B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500600A5 (enExample) | ||
| RU2010118467A (ru) | Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов | |
| JP2011500599A5 (enExample) | ||
| KR101235961B1 (ko) | 프로스타글란딘 ｄ２ 수용체의 ｎ,ｎ-이치환 아미노알킬비페닐 길항제 | |
| WO2010003127A2 (en) | Antagonists of prostaglandin d2 receptors | |
| JP2022050538A (ja) | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 | |
| RU2008144415A (ru) | Композиции, полезные в качестве ингибиторов потенциалзависимых натриевых каналов | |
| RU2010118481A (ru) | Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов | |
| JP2020526561A5 (enExample) | ||
| EP2245022A2 (en) | Antagonists of prostaglandin d2 receptors | |
| AU2019226215A1 (en) | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | |
| JP2011512359A (ja) | プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物 | |
| ES2232114T3 (es) | Derivados de cicloalqueno, procedimiento para su produccion, y uso. | |
| JP2012515166A5 (enExample) | ||
| JP5342451B2 (ja) | Ｐｄｅ４阻害剤として有用な置換アセトフェノン | |
| CN1474818A (zh) | 含有稠合杂环化合物或其盐的糖尿病预防或治疗药 | |
| JP2016500661A5 (enExample) | ||
| Nascimento et al. | Co-crystals of non-steroidal anti-inflammatory drugs (NSAIDs): Insight toward formation, methods, and drug enhancement | |
| WO2009145989A2 (en) | Aminoalkylphenyl antagonists of prostaglandin d2 receptors | |
| CN1368953A (zh) | 作为IL－1β和TNF－α的抑制剂的氨基二苯酮 | |
| JP4580866B2 (ja) | Ｔａｃｅのインヒビター | |
| RU2247719C2 (ru) | Аминобензофеноны как ингибиторы il-1 бета и tnf-альфа, фармацевтическая композиция и способ лечения и/или профилактики воспалительных заболеваний | |
| JPWO2020243488A5 (enExample) | ||
| EP2547199A2 (fr) | Nouvelles utilisations de composes de type esteramide | |
| JP5291124B2 (ja) | 新規なキナゾリン−２，４−ジオン誘導体、及びこれを含有する脳神経系疾患の予防及び治療用医薬組成物 |